MedCap Q2 2025: The rise, fall, and rise again - Redeye

Redeye updates its estimates and valuation following MedCap’s Q2 2025 report. MedCap beat our adjusted EBITA projection, and its return to y/y profit growth aligned with what we pencilled in. Recent M&A and organic development should fuel continued growth and margin expansion, while the company’s financial M&A capacity remains substantial even after a recent larger deal in Specialty Pharma.

Länk till analysen i sin helhet: https://www.redeye.se/research/1120433/medcap-q2-2025-the-rise-fall-and-rise-again?utm_source=finwire&utm_medium=RSS